B-MS beats estimates thanks to advance of Eliquis

5 February 2018
bristol-myers-squibb-big

US pharma major Bristol-Myers Squibb (NYSE: BMY) was on its way up in pre-market trading on Monday after reporting its fourth-quarter and full-year 2017 results.

The drugmaker recorded revenue for the quarter of $5.45 billion where analysts had estimated around $5.31 billion. The figure was 4% higher than in the same period of 2016.

Earnings per share (EPS), excluding special items, were $0.68 for the quarter, compared to estimates of $0.67 and the $0.63 of the 2016 period. EPS using generally accepted accounting principles (GAAP) showed a loss of $1.42, something attributed to the US tax reforms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical